论文部分内容阅读
冠状动脉内注射链激酶(STK)治疗急性心肌梗塞,能使冠状动脉阻塞患者迅速恢复灌注。但在注射 STK 前必须先做耗费较大的冠状动脉造影,以致延迟治疗,这就促使人们重新考虑静脉注射 STK。过去,由于病例选择、治疗开始时间、剂量和给药次数各异,故对静脉注射 STK 的估价不一。Schr(?)der等在起病6小时内静脉注射 STK,有50～60%的病人经造影证实冠状动脉恢复了灌注。为了进一步证实静脉注射 STK 的疗效,本文作者对81例患者于急性心肌梗塞早期快速静脉注射大剂量 STK,亦取得了很好的效果。方法:(1)选择病人的标准是:①起病3小时内;②心电图证实为穿壁性心肌梗塞;③无溶栓及抗
Coronary injection of streptokinase (STK) in the treatment of acute myocardial infarction, coronary occlusion patients can quickly resume perfusion. However, prior to injection of STK, coronary angiography has to be performed at a greater cost, leading to delay in treatment, prompting one to reconsider intravenous STK. In the past, the valuation of intravenous STK varied depending on the choice of case, the timing of treatment, the dosage and the number of dosing. Schr (?) Der intravenous injection of STK within 6 hours of onset, 50 to 60% of patients confirmed by coronary angiography perfusion recovery. In order to further confirm the efficacy of intravenous STK, the authors of this article 81 patients in the early acute myocardial infarction rapid intravenous injection of high-dose STK, also achieved good results. Methods: (1) The criteria for patient selection were: (1) onset within 3 hours; (2) ECG confirmed as transmyocardial infarction; (3) no thrombolysis and resistance